FDAnews
www.fdanews.com/articles/80801-riotech-pharmaceuticals-raises-gbp-3-4-million-in-private-financing-round

RIOTECH PHARMACEUTICALS RAISES GBP 3/4 MILLION IN PRIVATE FINANCING ROUND

September 12, 2005

RioTech Pharmaceuticals Limited (RioTech Pharma) today announced that it has successfully raised GBP750,000 (over $1.3 million) in a private financing round. The funds will drive the preclinical development of the Company's lead product, a novel interferon alpha-8 (IFN-alpha-8) chronic hepatitis C (CHC) therapy. In antiviral assays, IFN-alpha-8 is over 1000-fold more potent than IFN-alpha-2 (an established CHC therapy). RioTech Pharma has perfected a commercially compatible system to produce recombinant IFN-alpha-8, and is now well financed to progress this product through the next phase of development.

Canada NewsWire Group (http://www.newswire.ca/en/releases/archive/September2005/12/c8250.html)